Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others), By Indication (Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, and Others), By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, and Others), By Region, and Competition

The Global Cancer Gene Therapy Market is anticipated to witness an impressive growth during the forecast period. Growing demand for painless treatment at lower cost coupled with increasing aesthetic consciousness among the population significantly increase the demand for cancer gene therapy across different parts of the globe. Besides, growing awareness about advantages of using gene therapy and diagnosis along with increasing healthcare expenditure on cancer treatment across the globe is further expected to support the Cancer Gene Therapy Market during the forecast period. In 2022, an estimated 66,470 people (48,520 men and 17,950 women) will be diagnosed with head and neck cancer in the United States. Cancer is one of the deadliest diseases in the world, and it has been a significant concern for public health for decades. Despite the significant advances in cancer treatments, the disease remains a major threat to human life, and new innovative treatments are urgently needed. Gene therapy, which involves the use of genes to treat or prevent disease, has emerged as a promising therapeutic option for cancer. Gene therapy is a complex and expensive treatment option, and the high cost is a significant barrier to its widespread adoption. The high cost of gene therapy may limit its availability to only those who can afford it, creating disparities in access to care. Gene therapy is a relatively new and complex treatment option, and regulatory agencies around the world are still grappling with how to regulate and approve these treatments. The regulatory hurdles can slow down the approval process, delaying the availability of new treatments to patients. Gene therapy carries certain safety risks, such as immune reactions and off-target effects. These safety concerns must be addressed through rigorous preclinical and clinical testing to ensure the safety and efficacy of gene therapy treatments. Gene therapy is a relatively new treatment option, and there is limited clinical experience with these treatments. The lack of clinical experience can limit our understanding of the long-term safety and efficacy of gene therapy treatments. Gene therapy raises complex ethical questions, such as the use of gene editing technologies, the potential for genetic discrimination, and the potential for unintended consequences from altering genetic material. The use of gene therapy requires highly skilled personnel, including geneticists, immunologists, and cell biologists. The limited availability of trained personnel can be a significant barrier to the widespread adoption of gene therapy treatments. Cancer gene therapy involves the use of genetic material to target cancer cells. The genetic material can be delivered into the cancer cells using various methods, including viruses, liposomes, or nanoparticles. Once inside the cell, the genetic material can be used to either suppress the growth of the cancer cell or to stimulate the immune system to attack the cancer cells.

Increasing research and development activities

Increasing research and development activities and technological advancement with developed healthcare infrastructure is the major factor for the growth of the cancer gene therapy market during the forecast period. Government organizations are focusing on developed infrastructure with higher profit. Different type of innovative therapies is available for cancer therapy which is ethically accepted and increasing development of new products are expected to boost the market growth over the years. The growing regulatory environment has enhanced the demand for cancer gene therapy which will boost market growth during the forecast period. Due to their direct connection to consumer health, regulations are placed on producers to assure the release of products that are free from flaws which can drive market growth over the years. Some laws have been changed for preventing product recalls during post-marketing surveillance since any flaws in gene therapy goods could be disastrous for patients. However, the expansion of the cancer gene therapy market in the years to come will be aided by the growing availability of high-quality cancer gene therapy. In 2020, an estimated 276,480 new cases of invasive breast cancer will be diagnosed in women in the U.S. as well as 48,530 new cases of non-invasive (in situ) breast cancer. The rising prevalence of cancer is one of the primary drivers of the global cancer gene therapy market. According to the World Health Organization (WHO), cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Personalized medicine is an emerging field that focuses on tailoring medical treatment to individual patients based on their genetic makeup, lifestyle, and environment. Gene therapy is a key component of personalized medicine, and the growing demand for personalized medicine is driving the growth of the global cancer gene therapy market. Targeted therapies are designed to selectively target and kill cancer cells while leaving healthy cells unharmed. Gene therapy is a promising approach to targeted therapy, and the increasing focus on targeted therapies is driving the growth of the global cancer gene therapy market.

Growing advancement in gene therapy

Increasing prevalence rate of lifestyle disorders such as diabetes and obesity, excessive alcohol consumption, tobacco use, low physical activity, high body mass index and low intake of fruits and vegetables because of growing population is further expected to create a lucrative growth of the market during the forecast period. In march 2022, the National Heart Lung and Blood Institute granted USD 12 million to an Indiana University School of Medicine Researcher. This grant is for developing a major part of a gene therapy approach to safer and potentially curative treatments for hemophilia diseases. So different private and government organizations are investing for gene therapy for curing cancer diseases across the globe. Similarly, increasing demand for laboratory automation and growing awareness of preventative healthcare are the major factors which will boost the market growth over the years. The rise in cancer cases is the primarily affecting the growth of the industry, being the second largest death cause in the world. In 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States and 606,520 people will die from the disease. Over the years, there have been significant advancements in gene therapy technologies, including the development of new gene delivery methods, gene editing techniques, and gene regulation technologies. These advancements have significantly improved the efficacy and safety of gene therapy treatments, making them more attractive as a cancer treatment option. The growing investments in healthcare infrastructure, particularly in emerging economies, are also driving the growth of the global cancer gene therapy market. These investments are increasing the availability and accessibility of advanced healthcare technologies, including gene therapy treatments, which is expected to boost the demand for these treatments in the coming years.

Recent Development

• In Sept 2021, Adaptimmune collaborated with Genentech to develop allogeneic cell therapies indicated for the treatment of multiple cancers.
• In June 2021, Eisai and Bristol Myers Squibb agreed to partnered for the development and commercialization of Eisai's ADC, MORAb-202, for the treatment of advanced solid malignancies.
• In June 2021, GSK and iTeos Therapeutics partnered for developing EOS-448, an anti-TIGIT monoclonal antibody that had previously been approved in phase 1 for treatment of advanced solid malignancies.
• Luxturna: In 2018, Spark Therapeutics launched Luxturna, a gene therapy for the treatment of inherited retinal diseases caused by mutations in a specific gene. Luxturna was the first gene therapy approved by the FDA for a genetic disease and has shown significant clinical benefit in patients.
• Zolgensma: In 2019, Novartis launched Zolgensma, a gene therapy for the treatment of spinal muscular atrophy (SMA), a rare genetic disease that affects muscle strength and movement. Zolgensma is a one-time infusion that has shown significant clinical benefit in clinical trials and has been hailed as a breakthrough therapy.
• Tecartus: In 2020, Kite Pharma, a Gilead Company, launched Tecartus, a CAR T-cell therapy for the treatment of mantle cell lymphoma. Tecartus has shown promising results in clinical trials and was granted accelerated approval by the FDA in 2020.

Download Free Sample Report

Market Segmentation

The Global Cancer Gene Therapy Market can be segmented by therapy, indication, end user and by region. Based on therapy, the market can be segmented into Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others. Based on indication, the market can be segmented into Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, and Others. Based on end user, the market can be differentiated Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, and Others. Regionally, North America dominates the market among Asia Pacific, Europe, Middle East & Africa, and South America. Amongst the different countries, United States dominate the global cancer gene therapy market on account of growing demand for advanced therapy with low cost for curing the cancer diseases in the country.

Market Players

Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio-Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, Introgen Therapeutics Inc., OncoGenex Pharmaceuticals Inc., Merck KGaA are some of the leading players operating in the Global Cancer Gene Therapy Market.

Report Scope:

In this report, global cancer gene therapy systems market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Cancer Gene Therapy Market, By Therapy:

o    Oncolytic Virotherapy

o    Gene Induced Immunotherapy

o    Gene Transfer

o    Others

• Cancer Gene Therapy Market, By Indication:

o    Breast Cancer

o    Ovarian Cancer

o    Lung Cancer

o    Liver Cancer

o    Pancreatic Cancer

o    Prostate Cancer

o    Others

• Cancer Gene Therapy Market, By End User:

o    Biotechnology & Pharmaceutical Companies

o    Academic & Research Institutions

o    Others

• Cancer Gene Therapy Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• Germany
• United Kingdom
• Italy
• Spain
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Cancer Gene Therapy Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Cancer Gene Therapy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]